查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1641380

全球腸外營養市場：特色見解（2024-2029）

Global Parenteral Nutrition Market - Focused Insights 2024-2029
出版日期: | 出版商: Arizton Advisory & Intelligence | 英文 155 Pages | 訂單完成後即時交付

價格

預計2023年至2029年期間全球腸外營養市場規模的年複合成長率為 8.24%。

2023年，美國Regent推出了磷酸鉀注射液USP，功能與磷酸鉀類似。這款經 FDA 核准的產品以靜脈注射方式為無法透過食物或餵食管取得足夠磷的兒童和成人提供磷。2022年，大塚製藥株式會社獲得日本首個週邊靜脈營養液Enefluid注射液的批准。這種創新產品將脂肪和水溶性維生素、葡萄糖、電解質和氨基酸結合在一個雙室袋中。此項批准大大增強了公司的產品組合，並促進了公司市場的成長。

2022年，Fresenius Kabi完成對Ivenix, Inc.的收購，鞏固了其在美國輸液治療市場的地位。此次收購創造了全面的、領先業界的優質輸液治療產品線，使患者、客戶和利益相關者受益，並擴大了Fresenius Kabi的腸外營養產品組合。

2022年，Fresenius Kabi（Fresenius Kabi）宣布將在美國推出針對兒科患者的脂質注射乳劑（ILE）。研究包括足月嬰兒和早產嬰兒。本產品成為第一個也是唯一獲準用於各年齡層腸外營養的四油脂肪乳劑。

預混腸外營養（PN）的使用日益增加，反映了醫療保健產業對營養支持的安全性、效率和成本效益的關注。預混 PN 溶液是標準化、即用型營養物，減少了在護理點配製和手動製備的需要。這種便利性對於需要快速反應的醫院和診所尤其有用，例如急診和重症監護部門。預混配方簡化了準備過程，節省了醫療保健提供者的時間並降低了與手動混合營養素相關的人為錯誤的風險，這對患者安全非常重要。預混 PN 日益被採用的主要驅動因素之一是預混配方提供的更高的無菌性和穩定性。預混配方在受控環境中生產，以滿足嚴格的品質和安全標準，並最大限度地降低內部配製可能產生的污染風險。這種無菌性對於 PN 尤其重要，因為 PN 是直接注入血液的，即使是輕微的污染也可能導致嚴重的併發症。在醫療機構中，使用預混 PN 還可以更輕鬆地儲存、處理和運輸。這些製劑通常具有較長的保存期限和標準化的包裝，使其方便且多功能地用於各種護理環境中。

腸外營養（PN）市場面臨的一個主要挑戰是缺乏強有力的臨床證據來支持某些新技術和配方的有效性和安全性。 PN 的進步，包括新配方、管理系統和自動配製等創新技術，都具有良好的前景，但缺乏廣泛的臨床試驗和長期資料，限制了其廣泛應用。如果沒有足夠的臨床證據，醫療保健提供者可能不願意將新技術納入患者護理中，而更喜歡已證明安全有效的成熟方法。這可能會延遲採用可以改善患者治療效果、減少併發症並提供更個人化營養支援的創新技術。此外，監管機構在批准這些新技術之前可能會要求提供更多實質證據，這可能會延遲其上市。

本報告概述了全球腸外營養市場，提供了有關產品、營養素、患者群體、適應症、最終用戶和地區以及公司概況的趨勢的詳細資訊。

目錄

第1章 腸外營養市場概論

  • 執行摘要
  • 主要調查結果

第2章 腸外營養市場

  • 全球腸外營養市場收入預測（2020-2029年，十億美元）

第3章 腸外營養市場前景與機會

  • 腸外營養市場機會與趨勢
  • 腸外營養市場驅動因素
  • 腸外營養市場的限制因素

第4章 腸外營養市場區隔資料

  • 全球：依產品的預期收入（2020年至2029年，十億美元）
  • 全球：依營養分類的收入預測（2020-2029年，十億美元）
  • 全球：依病患群體的預期收入（2020年至2029年，十億美元）
  • 全球：依適應症的收入預測（2020年至2029年，十億美元）
  • 全球：依最終用戶預測的收入（2020年至2029年，十億美元）

第5章 主要地區概況

  • 北美：腸外營養市場收入預測（2020-2029年，十億美元）
    • 美國
    • 加拿大
  • 亞太地區：腸外營養市場收入預測（2020-2029年，十億美元）
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
  • 歐洲：腸外營養市場收入預測（2020-2029年，十億美元）
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
  • 拉丁美洲：腸外營養市場收入預測（2020-2029年，十億美元）
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東與非洲：腸外營養市場收入預測（2020-2029年，十億美元）
    • 土耳其
    • 南非
    • 沙烏地阿拉伯

第6章 腸外營養市場產業概況

  • 腸外營養市場 - 競爭格局
  • 腸外營養市場 - 主要供應商概況
  • 腸外營養市場 - 其他主要供應商
  • 腸外營養市場 - 主要策略建議

第7章 附錄

Product Code: AFI24184

The global parenteral nutrition market is expected to grow at a CAGR of 8.24% from 2023 to 2029.

RECENT VENDORS ACTIVITIES

  • In 2023, American Regent introduced Potassium Phosphates Injection USP, which functions similarly to Potassium Phosphates. This FDA-approved product provides phosphorus in intravenous fluids for children and adults who are unable to obtain sufficient phosphorus from food or feeding tubes.
  • In 2022, Otsuka Pharmaceutical Co., Ltd. received approval for ENEFLUID Injection, Japan's first peripheral parenteral nutrition solution. This innovative product combines fat and water-soluble vitamins, along with glucose, electrolytes, and amino acids, in a dual-chamber bag. The approval significantly enhanced the company's product portfolio and contributed to its market growth.
  • In 2022, Fresenius Kabi completed the acquisition of Ivenix, Inc., strengthening its position in the U.S. infusion therapy market. This acquisition created a comprehensive, industry-leading offering of premium infusion therapy products, benefiting patients, customers, and stakeholders, while expanding Fresenius Kabi's range of parenteral nutrition products.
  • In 2022, Fresenius Kabi announced that its Lipid Injectable Emulsion (ILE) would be available for pediatric patients in the U.S., including both full-term and preterm newborns. This product became the first and only four-oil lipid emulsion approved for use in parenteral nutrition across all age groups.

KEY TAKEAWAYS

  • By Product: The macronutrient segment holds the largest market share of 66%. The segmental growth is due to advancements in clinical understanding and patient-specific requirements.
  • By Nutrition: The compounded PN segment shows the highest growth of 10.33%, as they play a critical role in providing tailored nutritional solutions for patients with specific medical needs.
  • By Patient Group: The adult segment holds the largest market share due to malnutrition being a significant concern in adult populations.
  • By Indication: The short-term segment accounts for the largest market share, as short-term parenteral nutrition (PN) continues to be a critical tool in supporting patients when enteral nutrition (EN) is insufficient or contraindicated.
  • By End-User: The home care & long-term care settings segment shows the highest growth, as more patients with chronic conditions seek nutritional support at home to enhance quality of life and avoid hospital-acquired infections.
  • By Geography: North America accounted for the largest share of the global parenteral nutrition market, primarily driven by the increasing prevalence of malnutrition, particularly among hospitalized patients in the U.S.
  • Growth Factor: The global parenteral nutrition market is set to grow due to increased utilization of premixed PN formulations and growing preference for home parenteral nutrition.

MARKET TRENDS & DRIVERS

Increased Utilization of Premixed PN Formulations

The utilization of premixed parenteral nutrition (PN) formulations is on the rise, reflecting the healthcare industry's focus on safety, efficiency, and cost-effectiveness in delivering nutritional support. Premixed PN solutions are standardized nutrient formulas that come ready for use, reducing the need for compounding or manual preparation in healthcare settings. This convenience is especially valuable in hospitals and clinics where rapid response is necessary, such as emergency or critical care departments. Premixed formulations simplify the preparation process, saving time for healthcare providers and reducing the risk of human error associated with the manual mixing of nutrients, which is critical for patient safety. One of the major drivers behind the increased adoption of premixed PN is the enhanced sterility and stability it offers. Since premixed formulations are manufactured in controlled environments, they meet rigorous quality and safety standards, minimizing the risk of contamination that can arise from in-house compounding. This sterility is particularly crucial in PN, where even slight contamination can lead to severe complications due to direct bloodstream delivery. For healthcare facilities, using premixed PN also allows for easier storage, handling, and transportation, as these formulations typically have longer shelf lives and standardized packaging, making them convenient and versatile in various care settings.

Growing Preference for Home Parenteral Nutrition (HPN)

The growing preference for Home Parenteral Nutrition (HPN) reflects a shift toward patient-centered, at-home care, offering essential nutritional support for patients with long-term needs, such as gastrointestinal disorders and malabsorption syndromes. HPN enhances comfort, flexibility, and quality of life by allowing patients to receive treatment at home, reducing hospital visits, and freeing up healthcare resources for acute care. Technological advancements, such as portable infusion pumps and remote monitoring tools, have made HPN safer and more manageable for patients and caregivers, enabling healthcare providers to oversee progress remotely. This trend is further driven by healthcare policies promoting cost-effective, patient-focused care. HPN reduces hospitalization expenses and provides a viable alternative for long-term nutritional support. Improved insurance coverage in many regions has increased its accessibility, making HPN an increasingly preferred option for both patients and healthcare systems.

Growing Prevalence of Premature Births

The increasing prevalence of premature births globally is driving the demand for specialized neonatal care, including parenteral nutrition (PN). Premature infants, born before 37 weeks of gestation, cannot often consume or absorb adequate nutrition orally or enterally due to underdeveloped gastrointestinal systems, making PN critical for their growth and development. Rising premature birth rates, particularly in regions like Sub-Saharan Africa and parts of the U.S., have highlighted the need for nutrient-rich PN solutions that support growth, brain development, and immune function during critical early life stages. To address these needs, advancements in PN formulations enriched with essential nutrients such as trace elements, fatty acids, and micronutrients have improved neonatal care quality. These innovations reduce complications like nutrient imbalances and liver disease, improving survival rates and long-term outcomes for preterm infants in neonatal intensive care units (NICUs). As premature birth rates continue to rise, the emphasis on improving PN quality and safety grows, ensuring better support for vulnerable infants.

INDUSTRY RESTRAINTS

Lack of Clinical Evidence to Support Novel Technology

A key challenge in the parenteral nutrition (PN) market is the lack of robust clinical evidence to support the efficacy and safety of some novel technologies and formulations. While advances in PN, such as new formulations, delivery systems, and innovations like automated compounding, hold potential, the absence of extensive clinical trials and long-term data limits their widespread adoption. Without sufficient clinical evidence, healthcare providers may hesitate to incorporate new technologies into patient care, preferring established methods with proven safety profiles. This can slow down the adoption of innovations that could potentially improve patient outcomes, reduce complications, or offer more personalized nutritional support. Furthermore, regulatory agencies may require more substantial evidence before approving these new technologies, delaying their availability to the market.

SEGMENTATION INSIGHTS

INSIGHTS BY PRODUCT

The global parenteral nutrition market by product is segmented into macronutrients, automated compounds, and micronutrients. The macronutrients segment accounted for the largest market share of 66% in 2023. In the parenteral nutrition (PN) market, macronutrients such as carbohydrates, lipids, and amino acids form the core of nutritional formulas aimed at patients with compromised digestive functions or specific nutrient needs. The demand for PN with balanced macronutrient compositions has grown with advancements in clinical understanding and patient-specific requirements. Multichamber bags (MCBs) are increasingly popular, as they contain glucose, amino acids, and lipids in pre-compounded formats, streamlining the preparation and reducing error risks in both inpatient and outpatient settings. These bags are available in dual- and tri-chamber forms, with the latter containing all three primary macronutrients, which reduces manipulation and supports safer administration. The focus on macronutrient optimization aligns with the broader trends in the PN market, which is projected to grow as clinicians and manufacturers work together to improve product safety, standardization, and personalized care options.

By Product

  • Macronutrients
  • Automated Compounds
  • Micronutrients

INSIGHTS BY NUTRITION

The global parenteral nutrition market by nutrition is categorized into RTU/standard commercial PN and compounded PN. The compounded PN segment shows prominent growth, with the fastest-growing CAGR of 10.33% during the forecast period. Compounded parenteral nutrition (PN) plays a critical role in the global parenteral nutrition market, providing tailored nutritional solutions for patients with specific medical needs. Unlike standardized PN formulas, compounded PN is custom-made, allowing healthcare providers to adjust macronutrients, micronutrients, and fluid volumes to meet individual patient requirements. This approach is especially valuable for patients with unique metabolic demands or complex health conditions, such as critically ill patients or those with organ dysfunction, who require precise nutrient management. The ability to personalize nutritional content enhances treatment efficacy, reduces the risk of nutrient imbalances, and improves overall patient outcomes, making compounded PN a growing segment within the broader PN market.

By Nutrition

  • RTU/Standard Commercial PN
  • Compounded PN

INSIGHTS BY PATIENT GROUP

The global parenteral nutrition market by patient group is segmented into adults and pediatric. The adult segment dominates and holds the largest market share in 2023. The adult population relying on parenteral nutrition (PN) is growing due to conditions requiring intravenous nutritional support, such as short bowel syndrome, pancreatitis, Crohn's disease, and enterocutaneous fistulas. Total Parenteral Nutrition (TPN) is crucial for adults unable to absorb nutrients through the gastrointestinal tract. As malnutrition linked to various health issues rises, comprehensive nutritional assessments and TPN interventions are vital for improving patient outcomes. Standardized diagnostic frameworks will further enhance the management of adult malnutrition in healthcare systems.

By Patient Group

  • Adults
  • Pediatric

INSIGHTS BY INDICATION

Based on the indication, the short-term segment holds the largest share of the global parenteral nutrition market. The short-term parenteral nutrition (PN) market has evolved to address the metabolic needs of critically ill patients more effectively. Fat-based solutions, compared to glucose-heavy ones, reduce inflammation and stabilize blood sugar, suggesting they can mitigate risks like hyperglycemia. This advancement highlights the importance of tailoring PN to individual needs. Short-term PN serves as a bridge for patients requiring immediate stabilization, such as during preoperative bowel rest. However, PN's complexity demands strict oversight to prevent complications like infections and electrolyte imbalances. In lower-volume facilities, particularly U.S. hospitals, ensuring safety underscores the need for rigorous training and proper handling of formulations.

By Indication

  • Short-term
  • Long-term

INSIGHTS BY END-USER

Based on the end-user, the home care & long-term care settings segment shows significant growth with the fastest-growing CAGR of the global parenteral nutrition market during the forecast period. This growth is driven by the rising number of patients with chronic conditions who require long-term nutritional support but prefer to avoid hospital stays to improve their quality of life and reduce infection risks. Parenteral nutrition in-home care provides a cost-effective solution, allowing patients to manage their conditions comfortably while minimizing healthcare costs. Similarly, long-term care facilities, such as nursing homes, are increasingly adopting parenteral nutrition to support an aging population with complex health needs. Elderly patients with illnesses or age-related conditions that impair nutrient absorption rely on parenteral nutrition to maintain their health.

By End-Users

  • Hospitals
  • Home Care & Long-term Care Settings
  • Ambulatory Care Settings

GEOGRAPHICAL ANALYSIS

North America dominates and holds the largest market share in the global parenteral nutrition market in 2023. This growth is driven by an increasing prevalence of gastrointestinal diseases such as Crohn's disease, ulcerative colitis, and short bowel syndrome, which necessitate nutritional support through parenteral methods when patients cannot ingest food orally. The market's growth is further supported by the rising rates of chronic diseases. Approximately 60% of adults in the U.S. live with at least one chronic condition, and this figure is projected to increase significantly, leading to greater reliance on parenteral nutrition to meet dietary needs during treatment. Overall, as healthcare systems adapt to these rising demands, the parenteral nutrition market in North America is poised for significant expansion in the coming years.

APAC accounted for the second-largest share of the global parenteral nutrition market and shows the highest growth during the forecast period. The parenteral nutrition (PN) market in the Asia-Pacific (APAC) region is experiencing rapid growth, fueled by increasing chronic disease prevalence, a rising aging population, and growing awareness about malnutrition's impact on health. Several APAC countries, including China, India, and Japan, are seeing significant investments in healthcare infrastructure, which, combined with government efforts to improve nutritional health, is accelerating the adoption of clinical nutrition solutions, particularly parenteral nutrition. Chronic diseases, such as cancer, diabetes, and gastrointestinal disorders, are prevalent across APAC.

By Geography

  • North America
    • US
    • Canada
  • APAC
    • China
    • Japan
    • India
    • South Korea
    • Australia
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
  • Latin America
    • Brazil
    • Argentina
    • Mexico
  • Middle East & Africa
    • Turkey
    • South Africa
    • Saudi Arabia

COMPETITIVE LANDSCAPE

The global parenteral nutrition market report contains exclusive data on 26 vendors. The market is marked by intense competition, driven by the presence of several key players, including Baxter, B. Braun, Fresenius Kabi, JW Pharmaceutical, Sichuan Kelun Pharmaceutical, and Grifols. These companies hold a significant share of the market and are known for their comprehensive parenteral nutrition portfolios. They focus on innovations to improve nutrient delivery systems, increase efficiency, and enhance patient outcomes. Local and regional players are also emerging, especially in developing markets, where the need for effective nutrition management solutions is increasing. In regions such as Asia-Pacific and Latin America, these players often offer cost-effective solutions that address local needs. Moreover, emerging companies are increasingly focusing on personalized nutrition solutions, which are designed to meet the specific metabolic needs of individual patients.

Key Vendors

  • Baxter
  • B.Braun
  • Fresenius Kabi
  • JW Pharmaceutical
  • Sichuan Kelun Pharmaceutical
  • Grifols

Other Prominent Vendors

  • Aculife Healthcare
  • Albert David
  • Amanta Healthcare
  • American Regent
  • Axa Parenterals Ltd
  • BML Parenteral Drugs
  • Caritas Healthcare Pvt. Ltd
  • Eurofarma
  • Eurolife Healthcare Pvt. Ltd
  • ICU Medical
  • Otsuka
  • Pfizer
  • Enzymes Pharmaceuticals
  • Anhui Medipharma
  • Lxir Medilabs Pvt. Ltd
  • Nymak Pharma Ltd
  • Salius Pharma
  • Schwitz Biotech
  • Soxa formulations
  • Reviv

KEY QUESTIONS ANSWERED:

1. How large is the global parenteral nutrition market?

2. What are the latest trends in the global parenteral nutrition market?

3. Which product has the largest share of the global parenteral nutrition market?

4. Which region has the largest market share of the global parenteral nutrition market?

5. Who are the key players in the global parenteral nutrition market?

TABLE OF CONTENTS

CHAPTER - 1: Parenteral Nutrition Market Overview

  • Executive Summary
  • Key Findings

CHAPTER - 2: Parenteral Nutrition Market

  • GLOBAL: Projected Revenue of Parenteral Nutrition Market (2020-2029; $ Billions)

CHAPTER - 3: Parenteral Nutrition Market Prospects & Opportunities

  • Parenteral Nutrition Market Opportunities & Trends
  • Parenteral Nutrition Market Drivers
  • Parenteral Nutrition Market Constraints

CHAPTER - 4: Parenteral Nutrition Market Segmentation Data

  • GLOBAL: Projected Revenue by Product (2020-2029; $ Billions)
    • Macronutrients
    • Automated Compounds
    • Micronutrients
  • GLOBAL: Projected Revenue by Nutrition (2020-2029; $ Billions)
    • RTU/Standard Commercial PN
    • Compounded PN
  • GLOBAL: Projected Revenue by Patient group (2020-2029; $ Billions)
    • Adults
    • Pediatric
  • GLOBAL: Projected Revenue by Indication (2020-2029; $ Billions)
    • Short-term
    • Long-term
  • GLOBAL: Projected Revenue by End-user (2020-2029; $ Billions)
    • Hospitals
    • Home Care & Long-term Care Settings
    • Ambulatory Care Settings

CHAPTER - 5: Key Regions Overview

  • North America: Projected Revenue of Parenteral Nutrition Market (2020-2029; $ Billions)
    • Projected Revenue of Parenteral Nutrition Market in the US
    • Projected Revenue of Parenteral Nutrition Market in Canada
  • APAC: Projected Revenue of Parenteral Nutrition Market (2020-2029; $ Billions)
    • Projected Revenue of Parenteral Nutrition Market in China
    • Projected Revenue of Parenteral Nutrition Market in Japan
    • Projected Revenue of Parenteral Nutrition Market in India
    • Projected Revenue of Parenteral Nutrition Market in South Korea
    • Projected Revenue of Parenteral Nutrition Market in Australia
  • Europe: Projected Revenue of Parenteral Nutrition Market (2020-2029; $ Billions)
    • Projected Revenue of the Parenteral Nutrition Market in Germany
    • Projected Revenue of Parenteral Nutrition Market in France
    • Projected Revenue of Parenteral Nutrition Market in the UK
    • Projected Revenue of Parenteral Nutrition Market in Italy
    • Projected Revenue of Parenteral Nutrition Market in Spain
  • Latin America: Projected Revenue of Parenteral Nutrition Market (2020-2029; $ Billions)
    • Projected Revenue of Parenteral Nutrition Market in Brazil
    • Projected Revenue of Parenteral Nutrition Market in Mexico
    • Projected Revenue of the Parenteral Nutrition Market in Argentina
  • Middle East & Africa: Projected Revenue of Parenteral Nutrition Market (2020-2029; $ Billions)
    • Projected Revenue of the Parenteral Nutrition Market in Turkey
    • Projected Revenue of Parenteral Nutrition Market in South Africa
    • Projected Revenue of Parenteral Nutrition Market in Saudi Arabia

CHAPTER - 6: Parenteral Nutrition Market Industry Overview

  • Parenteral Nutrition Market - Competitive Landscape
  • Parenteral Nutrition Market- Key Vendor Profiles
  • Parenteral Nutrition Market- Other Prominent Vendors
  • Parenteral Nutrition Market - Key Strategic Recommendations

CHAPTER - 7: Appendix

  • Research Methodology
  • Abbreviations
  • About Arizton

LIST OF EXHIBITS

  • Exhibit 1: Market Size & Forecast - Global Parenteral Nutrition Market (2020-2029, $ BN)
  • Exhibit 2: Market Size & Forecast - Macronutrients (2020-2029, $ BN)
  • Exhibit 3: Market Size & Forecast - Automated Compounds (2020-2029, $ BN)
  • Exhibit 4: Market Size & Forecast - Micronutrients (2020-2029, $ BN)
  • Exhibit 5: Market Size & Forecast - RTU/Standard Commercial PN (2020-2029, $ BN)
  • Exhibit 6: Market Size & Forecast - Compounded PN (2020-2029, $ BN)
  • Exhibit 7: Market Size & Forecast - Pediatric Patient Group (2020-2029, $ BN)
  • Exhibit 8: Market Size & Forecast - Adult Patient Group (2020-2029, $ BN)
  • Exhibit 9: Market Size & Forecast - Short-term (2020-2029, $ BN)
  • Exhibit 10: Market Size & Forecast - Long-term (2020-2029, $ BN)
  • Exhibit 11: Market Size & Forecast - Hospitals (2020-2029, $ BN)
  • Exhibit 12: Market Size & Forecast - Home Care & Long-term Care Settings (2020-2029, $ BN)
  • Exhibit 13: Market Size & Forecast - Ambulatory Care Settings (2020-2029, $ BN)
  • Exhibit 14: Market Size & Forecast - Parenteral Nutrition Market in North America (2020-2029, $ BN)
  • Exhibit 15: Market Size & Forecast - Parenteral Nutrition Market in the US (2020-2029, $ BN)
  • Exhibit 16: Market Size & Forecast - Parenteral Nutrition Market in Canada (2020-2029, $ BN)
  • Exhibit 17: Market Size & Forecast - Parenteral Nutrition Market in APAC (2020-2029, $ BN)
  • Exhibit 18: Market Size & Forecast - Parenteral Nutrition Market in China (2020-2029, $ BN)
  • Exhibit 19: Market Size & Forecast - Parenteral Nutrition Market in Japan (2020-2029, $ BN)
  • Exhibit 20: Market Size & Forecast - Parenteral Nutrition Market in India (2020-2029, $ BN)
  • Exhibit 21: Market Size & Forecast - Parenteral Nutrition Market in South Korea (2020-2029, $ BN)
  • Exhibit 22: Market Size & Forecast - Parenteral Nutrition Market in Australia (2020-2029, $ BN)
  • Exhibit 23: Market Size & Forecast - Parenteral Nutrition Market in Europe (2020-2029, $ BN)
  • Exhibit 24: Market Size & Forecast - Parenteral Nutrition Market in Germany (2020-2029, $ BN)
  • Exhibit 25: Market Size & Forecast - Parenteral Nutrition Market in France (2020-2029, $ BN)
  • Exhibit 26: Market Size & Forecast - Parenteral Nutrition Market in the UK (2020-2029, $ BN)
  • Exhibit 27: Market Size & Forecast - Parenteral Nutrition Market in Italy (2020-2029, $ BN)
  • Exhibit 28: Market Size & Forecast - Parenteral Nutrition Market in Spain (2020-2029, $ BN)
  • Exhibit 29: Market Size & Forecast - Parenteral Nutrition Market in Latin America (2020-2029, $ BN)
  • Exhibit 30: Market Size & Forecast - Parenteral Nutrition in Mexico (2020-2029, $ BN)
  • Exhibit 31: Market Size & Forecast - Parenteral Nutrition in Brazil (2020-2029, $ BN)
  • Exhibit 32: Market Size & Forecast - Parenteral Nutrition in Argentina (2020-2029, $ BN)
  • Exhibit 33: Market Size & Forecast - Parenteral Nutrition in the MEA (2020-2029, $ BN)
  • Exhibit 34: Market Size & Forecast - Parenteral Nutrition in Turkey (2020-2029, $ BN)
  • Exhibit 35: Market Size & Forecast - Parenteral Nutrition in South Africa (2020-2029, $ BN)
  • Exhibit 36: Market Size & Forecast - Parenteral Nutrition in Saudi Arabia (2020-2029, $ BN)

LIST OF TABLES

  • Table 1: Global Parenteral Nutrition Market (2020-2029, $ BN)
  • Table 2: Global Parenteral Nutrition Market by Product (2020-2029, %)
  • Table 3: Global Parenteral Nutrition Market by Product (2020-2029, $ BN)
  • Table 4: Global Parenteral Nutrition Market by Nutrition (2020-2029, %)
  • Table 5: Global Parenteral Nutrition Market by Nutrition (2020-2029, $ BN)
  • Table 6: Global Parenteral Nutrition Market by Patient Group (2020-2029, %)
  • Table 7: Global Parenteral Nutrition Market by Patient Group (2020-2029, $ BN)
  • Table 8: Global Parenteral Nutrition Market by Indication (2020-2029, %)
  • Table 9: Global Parenteral Nutrition Market by Indication (2020-2029, $ BN)
  • Table 10: Global Parenteral Nutrition Market by End-user (2020-2029, %)
  • Table 11: Global Parenteral Nutrition Market by End-user (2020-2029, $ BN)
  • Table 12: Global Parenteral Nutrition Market by Geography (2020-2029, %)
  • Table 13: Global Parenteral Nutrition Market by Geography (2020-2029, $ BN)